UChicago Medicine

https://www.uchicagomedicine.org/

 

UChicago Annual Updates from ASH 2019
Avatar

ASH 2019 Updates on CAR T Cell Therapy in CLL/SLL: Liso-cel Active in Pretreated R/R CLL/SLL & Strategies to Mitigate Toxicity in CAR T Cell Therapy

By UChicago Annual Updates from ASH 2019 FEATURING Peter Riedell
By UChicago Annual Updates from ASH 2019 FEATURING Peter Riedell
11 views
March 20, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
Annual Updates from ASH 2019
16:52
UChicago Annual Updates from ASH 2019

Hereditary Hematopoietic Malignancies: What to Look For, and What to…

Feat. M. Drazer
25:56
UChicago Annual Updates from ASH 2019

Inherited Predisposition to Myeloid Hematologic Malignancies: Why Do…

Feat. S. Feurstein
17:22
UChicago Annual Updates from ASH 2019

BCL2 Inhibition in Myeloid Malignancies: Venetoclax + Azacitidine in…

Feat. O. Odenike
12:07
UChicago Annual Updates from ASH 2019

Updates on Myeloid Malignancies: JAK in MF, TGFb Inhibition in MF an…

Feat. O. Odenike
12:13
UChicago Annual Updates from ASH 2019

Highlights from ASH on ALL: Role of AlloSCT in CR1 for Young Adults …

Feat. W. Stock
07:26
UChicago Annual Updates from ASH 2019

Highlight from ASH on ALL: Frontline Therapy in Older Adults & D…

Feat. W. Stock
10:45
UChicago Annual Updates from ASH 2019

Updates on CAR-T Treatment of ALL: Prognosticators of Response, Dual…

Feat. W. Stock
13:28
UChicago Annual Updates from ASH 2019

ASH 2019 Updates in Multiple Myeloma: Early Intervention in High Ris…

Feat. J. Jasielec
16:33
UChicago Annual Updates from ASH 2019

ASH 2019 Updates in R/R Multiple Myeloma: Prolonged PFS with KdD, Ve…

Feat. J. Jasielec
09:30
UChicago Annual Updates from ASH 2019

ASH 2019 Updates on CAR T Cell Therapy in DLBCL: Liso-cel has Favora…

Feat. P. Riedell
05:40
UChicago Annual Updates from ASH 2019

ASH 2019 Updates on CAR T Cell Therapy in Mantle Cell Lymphoma: KTE-…

Feat. P. Riedell
13:18
UChicago Annual Updates from ASH 2019

ASH 2019 Updates on CAR T Cell Therapy in CLL/SLL: Liso-cel Active i…

Feat. P. Riedell
08:12
UChicago Annual Updates from ASH 2019

ASH 2019 Updates on PET Directed Therapy for Early Stage DLBCL

Feat. J. Kline
12:46
UChicago Annual Updates from ASH 2019

ASH 2019 Updates on FL: Obinutuzimab + Lenalidomide in Frontline Set…

Feat. J. Kline
10:07
UChicago Annual Updates from ASH 2019

ASH 2019 Updates on Hodgkin Lymphoma: Frontline Brentuximab + Nivo i…

Feat. J. Kline
15:37
UChicago Annual Updates from ASH 2019

ASH 2019 Updates on Treatment of Young 'Fit' CLL Pts: Impr…

Feat. N. Jain
14:45
UChicago Annual Updates from ASH 2019

ASH 2019 Treatment of Older FCR Ineligible CLL Pts: 5 Years Follow‐u…

Feat. N. Jain
09:43
UChicago Annual Updates from ASH 2019

ASH 2019 Updates in R/R CLL: PFS and OS Benefit with VenR, Associati…

Feat. N. Jain